Investigator

Yarden Kezerle

Acting Director · Shaare Zedek Medical Center, Pathology

YKYarden Kezerle
Papers(1)
The significance of l…
Collaborators(2)
Benzion SamueliSharon Davidesko
Institutions(2)
Ben Gurion University…National Health Servi…

Papers

The significance of lower uterine segment involvement in endometrial cancer

Limited data suggests lower uterine segment involvement (LUSI) in endometrial cancer may be associated with other poor prognostic factors. We assessed the unclear impact of LUSI on prognosis in endometrial cancer. ology: A revision of pathological samples following surgical staging between the years 2002-2022 was performed and clinical data collected from patients' records. Characteristics and outcomes of women with and without LUSI were compared and analysed. Kaplan Meyer survival curves compared overall survival (OS) and progression-free survival (PFS). 429 women were included, of which 45 (10.5%) had LUSI. No differences were found between the groups regarding demographic or clinical characteristics. LUSI was significantly associated with lympho-vascular space invasion (40% vs. 22% p = 0.01), lymph node involvement (6.4% vs. 9.1%, p = 0.05), shorter PFS (4 vs. 5.5 years, p = 0.01) and OS (5.6 vs. 11.5 years, p = 0.03). Multivariate analysis showed higher hazard ratios for OS and PFS (1.55 95%CI 0.79-3.04 and 1.29 95%CI 0.66-2.53, respectively) but these were insignificant even in a sub-analysis of endometrioid histology (1.76 95%CI 0.89-3.46 and 1.35 95%CI 0.69-2.65, respectively). A trend towards decreased PFS and OS was demonstrated in the Kaplan Meyer survival curves for all cases (log rank test p = 0.5 and 0.29 respectively), endometrioid histology (log rank test p = 0.06 and 0.51 respectively) and early-stage disease (log rank test p = 0.63 and 0.3 respectively). LUSI may be related to poorer outcome of endometrial cancer and may represent an additional factor to consider when contemplating adjuvant treatment, especially in endometrioid-type and early-stage disease.

20Works
1Papers
2Collaborators

Positions

2025–

Acting Director

Shaare Zedek Medical Center · Pathology

2024–

Servive director - Lung Pathology

Shaare Zedek Medical Center · Pathology

2022–

Lead physician - Molecular Pathology

Soroka Medical Center · Pathology

2021–

Attending physician - General Pathology

Soroka Medical Center · Pathology

2013–

Junior Staff Lecturer, laboratory instructor

Ben-Gurion University of the Negev · Medicine

2011–

Chief Resident

Soroka Medical Center · Pathology

Education

2007

Medical Doctor

Universidade de São Paulo · Medicine

2000

Faculdade de Tecnologia de São Paulo · Data Processing

Country

IL